Compare HON & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HON | BMY |
|---|---|---|
| Founded | 1885 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8B | 123.7B |
| IPO Year | 2011 | N/A |
| Metric | HON | BMY |
|---|---|---|
| Price | $223.66 | $57.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 16 |
| Target Price | ★ $252.23 | $61.81 |
| AVG Volume (30 Days) | 3.2M | ★ 9.8M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 2.09% | ★ 4.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.36 | N/A |
| Revenue | ★ $36,529,000,000.00 | N/A |
| Revenue This Year | $6.80 | N/A |
| Revenue Next Year | $5.86 | N/A |
| P/E Ratio | $30.98 | ★ $17.26 |
| Revenue Growth | ★ 12.92 | N/A |
| 52 Week Low | $179.36 | $42.52 |
| 52 Week High | $248.18 | $62.89 |
| Indicator | HON | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 43.26 |
| Support Level | $220.02 | $56.45 |
| Resistance Level | $242.47 | $62.47 |
| Average True Range (ATR) | 4.49 | 1.27 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 27.11 | 23.20 |
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.